|
|
UNDERSTANDING STALEVO therapy
STALEVO is indicated for
certain patients with Parkinson's disease experiencing symptom
reemergence due to levodopa "wearing-off."
|
|
|
|
|
In fact, STALEVO extends the benefits of carbidopa/levodopa. STALEVO is the
most recent advance in levodopa therapy. It contains:
|
|
|
- Carbidopa, which inhibits the action of dopa decarboxylase, an
enzyme in the body that breaks down levodopa, making more dopamine
available to receptors in the brain
- Levodopa, which is converted by the body into dopamine to replace,
or supplement, the dopamine no longer produced by the brain, is the most
widely prescribed treatment for Parkinson's disease
- Entacapone, which is added to inhibit the action of COMT, another enzyme in the body that breaks down levodopa, to further
inhibit the breakdown of levodopa in the body before it reaches the brain
|
|
|
Because STALEVO contains entacapone, it provides a more persistent presence
of levodopa in the body, leading to more consistent symptom control than carbidopa/levodopa alone.
|
|
|
|
|
|
Parkinson's disease is caused by a shortage of dopamine. Levodopa turns into dopamine
when it enters the brain. When your loved one takes carbidopa/levodopa, only a small
amount of the drug can exert its effect because the body has multiple mechanisms to
break it down quickly before it has a chance to enter the brain. STALEVO blocks 2 mechanisms
that break down levodopa, allowing more of it to reach the brain, enhancing
and optimizing the effects of levodopa.
|
|
|
|
For patients with PD experiencing symptom reemergence due to levodopa "wearing-off."
STALEVO may deliver smoother and steadier levels of levodopa to the
brain in an extended, more consistent manner. Clinical studies prove that when
carbidopa, levodopa, and entacapone (the 3 components in STALEVO) are combined,
patients have better control of symptoms for longer periods of time—an average of almost an additional hour and a half each day (1.4 hours).
|
|
|
|
Talk to your loved one's health care professional (HCP) if you have questions about STALEVO.
|
|
|
|
|
|
STALEVO is clinically proven to improve functionality and has
been shown to deliver more active time during the day—an average of almost an hour and
a half each day (1.4 hours). So the person you care for can enjoy more time
with fewer symptoms.
|
|
|
|
Talk to your loved one's HCP if you have questions about STALEVO.
|
|
|
|
The person you care for can use STALEVO instead of carbidopa/levodopa
and COMTAN® (entacapone) 200 mg tablets, if he or she has been taking those medicines
as separate tablets.
|
|
|
|
For patients with PD experiencing symptom reemergence due to levodopa "wearing-off,"
STALEVO can be used to replace carbidopa/levodopa.
|
|
|
|
|
STALEVO is supplied as tablets in 6 strengths
- STALEVO 50 (containing 12.5 mg carbidopa, 50 mg levodopa, and 200 mg entacapone)
- STALEVO 75 (containing 18.75 mg carbidopa, 75 mg levodopa, and 200 mg entacapone)
- STALEVO 100 (containing 25 mg carbidopa, 100 mg levodopa, and 200 mg entacapone)
- STALEVO 125 (containing 31.25 mg carbidopa, 125 mg levodopa, and
200 mg entacapone)
- STALEVO 150 (containing 37.5 mg carbidopa, 150 mg levodopa, and 200 mg entacapone)
- STALEVO 200 (containing 50 mg carbidopa, 200 mg levodopa, and 200 mg entacapone)
|
|
|
|
|
 |
 |
|
|
|
|
|
Know what to expect from STALEVO therapy
|
|
|
|
|
 |
|
|
|
|
|
Don't forget to take care of yourself
|
|
|
|
|
|
 |
|
|
|
|
|
Find support and resources
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
 |
Use of website is governed by the Terms of Use and Privacy Statement.
Copyright ©2013 Novartis Pharmaceuticals Corporation. All rights reserved. |
| |
|
| 4/11 - SLV-1023900 |
| |
|
